Randomized Phase 2 study to evaluate 2 dose levels of Imetelstat in patients with myelofibrosis

To determine the activity of 2 Dose levels of Imetelstat in subjects with Intermediate-2 or high risk myelofibrosis relapsed/refractory to Janus Kinase inhibitor

Primary Sponsor:
Janssen

Prinicipal Investigator:
Robert Siegel, MD

Are you interested in more information on this clinical trial?

First Name *
Last Name *
Email *
Street Address *
City *
State *
Zip Code *
Phone Number 
     
Verification Code *

Please type what you see (all uppercase):